Latest News in the pharma Industry

Particle Sciences to open new commercial facility

15 Oct 2018

New facility will offer customers the full range of services from development through to commercial-scale manufacturing

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Pharma manufacturers warned to invest in continuous manufacturing

11 Oct 2018

CMOs hit by reduced volumes of opioid manufacturing from DEA quota changes, but cannabis sales to ignite.

Ajinomoto Althea and OmniChem Combine to Form Ajinomoto Bio-Pharma Services, Reflecting a Collective Range of Services Offered to the Bio-Pharma Industry

10 Oct 2018

Ajinomoto Althea and OmniChem, global leaders in large and small molecule contract manufacturing, announced that they are integrating as a unified CDMO and operating as Ajinomoto Bio-Pharma Services

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

New formulation modelling successes using ex vivo tissue

9 Oct 2018

One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Symbiosis secures FDA viral vector process approval

5 Oct 2018

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Dow Silicones Investment Roadmap Into Single-Use Solutions

5 Oct 2018

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Samsung BioLogics’ End-to-End service to maximize client satisfaction

4 Oct 2018

Samsung BioLogics was established in April 2011, and is headquartered in Incheon, South Korea. Samsung BioLogics provides an end-to-end service for contracted biopharmaceutical production from cell-line development, process development, and commercial ...